AM PLICA BIO SEC FORM D REVIEW
Amplica Bio, Inc. entered the SEC record on September 11, 2026 with one of the smallest initial raises in the current biotechnology filing set. The Delaware corporation was formed in 2026, lists 2810 N Church Street, Suite 90465 in Wilmington as its principal business address and classifies itself as a biotechnology company. Its Form D reports a first sale on September 2, 2026, an indefinite offering under Rule 506(b), $30,000 sold to one investor and no fixed amount remaining because the issuer selected "Indefinite" for the total offering. The securities are described as both equity and Simple Agreements for Future Equity, or SAFEs. No sales commissions, finder fees or related-person payments were reported, and Amplica declined to disclose revenue. The correct takeaway is therefore not that Amplica has completed a major venture round, but that it has begun a private financing program and had accepted only a small initial investment when the filing was submitted.
The management evidence is significantly richer than the corporate disclosure. The Form D identifies Kush Daksheish Mehta as an executive officer and director, while Kaustav Aras Gopinathan is listed as an executive officer. Mehta signed the filing as Chief Business Officer. Public academic records show that Kush Mehta earned both undergraduate and master's degrees in bioengineering from the University of Pennsylvania, where his research included mesenchymal stem-cell mechanobiology and cell-matrix interactions. His later professional history includes healthcare product and digital-health roles, including work associated with Mount Sinai and other healthcare technology environments. That background suggests experience translating biomedical concepts into products and operational workflows, but Amplica has not publicly explained whether Mehta's role is primarily commercial, product-focused, fundraising-oriented or related to clinical development.
Kaustav Gopinathan provides the strongest scientific signal. Harvard and MIT records identify him as a physician-scientist trained through the Harvard-MIT Health Sciences and Technology program, with an MIT electrical-engineering background and a Harvard PhD in biophysics. His doctoral dissertation, "Microfluidic Transistors for the Control of Liquids and Particles," explored systems capable of controlling fluid and particle flow using transistor-like architectures. Patent records identify Gopinathan and Massachusetts General Hospital researcher Mehmet Toner as inventors on intellectual property titled "Fluidic Transistors and Uses Thereof," with General Hospital Corporation listed as the assignee in public patent databases. Gopinathan also appears on more recent cancer-research work involving circulating tumor cells and dynamic monitoring of antibody-drug conjugates. These records establish a legitimate scientific background in microfluidics, diagnostics, biotechnology and medical devices, but they do not by themselves establish what Amplica Bio is developing.
That distinction is particularly important for this case. A common research error would be to see Gopinathan's patent history and conclude that Amplica Bio owns or commercializes his microfluidic-transistor inventions. The available patent record instead identifies General Hospital Corporation as the assignee of the published applications reviewed. FilingDossier did not identify a public assignment, exclusive license or corporate announcement transferring that intellectual property to Amplica Bio. Amplica may ultimately be developing technology related to microfluidics, diagnostics, cell analysis, genomic workflows or an entirely different biotechnology application; the current public evidence is insufficient to determine which. Until Amplica discloses a product, patent assignment, licensing agreement, scientific abstract, clinical program or official website, its precise technical thesis should remain classified as unconfirmed.
The corporate footprint is correspondingly sparse. FilingDossier did not identify a standalone website that could be confidently matched to Amplica Bio, Inc., CIK 0002154543, the Wilmington address, Kush Mehta and Kaustav Gopinathan. This creates a meaningful name-resolution problem because similarly spelled biotechnology brands and companies exist, and search results for "Amplica" can easily drift toward unrelated businesses or toward "Amplifica," a separate biotechnology name used elsewhere. The SEC issuer should therefore be identified by its exact legal name, CIK and officers rather than by a loosely matching web domain. The Wilmington address itself also deserves careful interpretation: 2810 N Church Street is used by numerous Delaware entities and corporate-service arrangements, so it does not establish the location of laboratories, offices or manufacturing operations. Investors should determine where Amplica's actual scientific work is being conducted and whether any university or hospital facilities remain involved.
The SAFE structure adds another layer of uncertainty. Amplica's Form D checks both equity and "Simple Agreement for Future Equity," meaning at least part of the financing may convert into shares later according to contract-specific terms. The filing does not disclose valuation cap, discount, most-favored-nation provisions, pro-rata rights, conversion trigger, maturity economics or whether all investors receive the same terms. Because only $30,000 had been sold to one investor, the company's capitalization may still be extremely fluid. A later financing could establish a very different valuation or ownership structure. Early investors should therefore review not only the SAFE itself but also authorized shares, founder equity, option pool, intellectual-property assignments and any university or hospital licensing obligations that could affect ownership or future dilution.
KEY FINDINGS Amplica Bio, Inc. is a Delaware biotechnology corporation formed in 2026. Its September 11, 2026 Form D reports an indefinite Rule 506(b) offering with $30,000 sold to one investor and a first sale on September 2. The offering includes equity and SAFEs. Kush Daksheish Mehta is listed as an executive officer and director and signed the filing as Chief Business Officer; Kaustav Aras Gopinathan is listed as an executive officer. Both have credible biomedical backgrounds, but Amplica itself remains effectively stealth. No independently verified corporate website, public product pipeline, clinical program, fundraising announcement or technology-license disclosure was identified during this review. The most important diligence question is therefore whether Amplica is commercializing technology derived from its founders' prior academic work or pursuing a different biotechnology platform altogether.
SEC FINANCING STRUCTURE SEC File Number: 021-597157 Form D Filing Date: September 11, 2026 Year Formed: 2026 Federal Exemption: Rule 506(b) Security Types: Equity and Simple Agreement for Future Equity Remaining: Indefinite Minimum Investment Reported: $0 Sales Commissions: $0 Finder Fees: $0 Related-Person Payments: $0 Revenue Range: Declined to disclose Offering Duration: Not intended to last more than one year Business Combination: No
SCIENTIFIC FOUNDER PENETRATION Kaustav Aras Gopinathan: Harvard-MIT Health Sciences and Technology MD-PhD training. PhD in Biophysics. MIT undergraduate background in Electrical Engineering. Doctoral research: Microfluidic Transistors for the Control of Liquids and Particles. Research areas publicly described: microfluidics, genomics, computational biology, medical devices and biological control systems. Academic affiliation: Massachusetts General Hospital / Harvard Medical School research ecosystem. Patent evidence: Named inventor with Mehmet Toner on "Fluidic Transistors and Uses Thereof." Patent assignee identified in reviewed public filings: General Hospital Corporation. Recent scientific work: Co-author on research involving circulating tumor cells and monitoring response to antibody-drug conjugates in breast cancer.
Kush Daksheish Mehta: University of Pennsylvania BSE and MSE in Bioengineering. Academic research involving mesenchymal stem-cell mechanobiology. Published work connected to N-cadherin, extracellular-matrix mechanosensing and stem-cell fate. Subsequent professional experience in healthcare technology, digital health and product development. SEC role at Amplica: Executive Officer, Director and Chief Business Officer / Form D signatory.
INTELLECTUAL-PROPERTY QUESTION The public record supports a strong scientific history for Gopinathan but does not yet establish that Amplica Bio owns the patents associated with his academic research. Patent records reviewed identify General Hospital Corporation as assignee of the fluidic-transistor family. Investors should therefore request: Any license from Massachusetts General Hospital or General Hospital Corporation. Any assignment of founder-created IP to Amplica Bio. Any new Amplica-owned provisional or non-provisional patent applications. Conflict-of-interest or sponsored-research agreements with Harvard, MIT or MGH. Documentation showing which inventions were created before and after Amplica's formation. Freedom-to-operate analysis for the company's intended commercial product.
WEBSITE / ENTITY PENETRATION Exact Legal Name: Amplica Bio, Inc. Corporate Email: Not independently confirmed SEC Address: 2810 N Church St, Suite 90465, Wilmington, DE 19802 SEC Phone: 646-907-9591 Address interpretation: Delaware corporate/business-service style address; not independently verified as laboratory location Executive identity: Confirmed through Form D Scientific founder history: Independently verifiable Product identity: Not independently confirmed Patent ownership by Amplica: Not confirmed ClinicalTrials.gov program: None confidently matched during this review FDA product record: None confidently matched during this review Name-confusion risk: High because similarly named biotechnology entities and "Amplifica" search results can be mistaken for Amplica Bio
WHY THE STEALTH STATUS MATTERS Amplica's lack of a public website is not automatically negative; many biotechnology companies remain in stealth while intellectual property, licensing and early proof-of-concept work are being established. However, stealth materially limits external verification. Investors currently cannot independently confirm the company's lead indication, development stage, target biology, product architecture, preclinical dataset, laboratory site, employees, scientific advisers or planned regulatory pathway. The scientific backgrounds of the officers therefore carry more weight than they normally would, making documentary diligence on IP ownership and corporate capitalization especially important.
CORE INVESTOR QUESTIONS Investors should determine exactly what Amplica Bio is developing and whether the lead program is a therapeutic, diagnostic, research tool, medical device or enabling biotechnology platform; identify where research and development physically occurs; obtain all founder and employee invention-assignment agreements; verify whether any Massachusetts General Hospital, Harvard or MIT technology has been licensed to the company; review the SAFE valuation cap, discount and conversion provisions; establish founder ownership and option-pool dilution; identify the company's scientific advisers and employees; determine how much capital is required to reach its next technical milestone; obtain preclinical or prototype data; understand whether FDA clearance, approval or laboratory regulation will eventually be required; and establish whether the initial $30,000 investment represents founder-related capital, an external investor or the beginning of a larger institutional raise.
CORE RISKS Amplica is an extremely early-stage issuer with minimal disclosed financing and virtually no public corporate operating information. Only one investor had purchased $30,000 of securities when the Form D was filed. The company has not publicly established a product or commercial model, and the absence of a verified website makes independent validation difficult. Academic credentials and patent history can strengthen founder credibility but do not establish that the company owns the underlying inventions or that those inventions can be commercialized. Biotechnology development also carries scientific reproducibility, intellectual-property, regulatory, manufacturing and financing risks. If Amplica remains dependent on technology owned by an academic institution, licensing economics and field-of-use restrictions could materially affect future value.
SEC SNAPSHOT SEC File No.: 021-597157 Film No.: 261373155 Filed: September 11, 2026 Formation Year: 2026 Exemption: Rule 506(b) Security: Equity + SAFE Revenue Range: Declined to disclose Sales Commissions: $0 Finder Fees: $0 Related-Person Proceeds: $0 Executive Officer / Director: Kush Daksheish Mehta Executive Officer: Kaustav Aras Gopinathan Form D Signatory: Kush Mehta, Chief Business Officer
PRIMARY EVIDENCE REVIEWED SEC Form D filed September 11, 2026 for Amplica Bio, Inc. SEC EDGAR filing index confirming CIK 0002154543 and File No. 021-597157. Harvard-MIT Health Sciences and Technology records for Kaustav Gopinathan. Harvard Biophysics Graduate Program profile for Kaustav Gopinathan. Harvard dissertation record for Microfluidic Transistors for the Control of Liquids and Particles. U.S. and international patent records for Fluidic Transistors and Uses Thereof. Massachusetts General Hospital / Harvard-associated research publications involving Kaustav Gopinathan. University of Pennsylvania Bioengineering / McKay Orthopaedic Research Laboratory records for Kush Mehta. Public professional-history material concerning Kush Mehta's healthcare technology and product work.
IMPORTANT FORM D NOTICE Amplica Bio's Form D does not state that the company raised a large institutional round. It reports an indefinite offering with only $30,000 sold to one investor as of September 11, 2026. The filing also does not identify Amplica's product or connect it to Kaustav Gopinathan's academic patent portfolio. Public patent records identify General Hospital Corporation as assignee of the fluidic-transistor applications reviewed. Accordingly, those inventions should not be described as Amplica-owned technology unless licensing or assignment evidence becomes available. Form D is an exempt-offering notice and does not constitute SEC approval of Amplica Bio, its founders, technology, financing terms or future products.